Jakarta, Indonesia (May 12, 2022) —Today, the International Pharmaceutical Manufacturers
Group of Indonesia (IPMG) announced that its Executive Director Parulian Simanjuntak, is
retiring as of May 27, 2022 after 19 years with the association.
“The Board of Directors is so grateful for Pak Anggi's many contributions
over the past 19 years as Executive Director. Pak Anggi has demonstrated
commitment, integrity and professionalismas IPMG navigated the
opportunities and challenges of the Indonesian pharmaceutical sector in the
broader national health-care industry. Perhaps above all else, Pak Anggi will
be recognized for his resolute dedication to help IPMGtake the lead in
driving greater transparency and the highest ethical standards of interaction with the
healthcare community and patients,” said Ait-Allah Mejri, Board Chair.
Welcome Inge Kusuma – New Executive Director
The IPMG Board of Directors is pleased to announce the appointment of Inge
Kusuma as its new Executive Director with effect from 1 June 2022.
“The Board conducted a wide search for a leaderwith Inge's depth of
experience and management expertise as well as her ability to work
collaboratively in meeting the ever-changing challenges faced by our sector.
With Inge’s leadership and unwavering commitment to serving patients, IPMG is poised to
strengthen its role of responsible health partner. I genuinely look forward to working with Inge
and the Board to continue serving patients and delivering value for our members,” noted Mr.
With over 25 years of experience in executive management and commercial operations within
the biotech and pharmaceutical industries, Inge has occupied positions of increasing
responsibility in leading healthcare companies. At Roche, she was the Country Head in
Vietnam before moving to AstraZeneca, as Country President in Thailand, and most recently,
as Oncology Brand Directorfor International Oncology Team. Inge attained her bachelor of
medicine from Maranatha Christian University and Master of Management from Gadjah Mada
IPMG represents the world’s leading innovative biopharmaceutical research companies, which
are operating in Indonesia and devoted to discovering and developing medicines and vaccines
that enable patients worldwide to live longer, healthier and more productive lives. Since 2002,
IPMG member companies have introduced more than 900 state-of-the art products into
Indonesia to treat cancer, infectious diseases, cardiovascular diseases, and other diseases.
IPMG members currently employ over 10,000 Indonesians who are working as true partners of
the Indonesia health community in order to increase the national availability of medicines and
vaccines, and promote pro-growth and pro-innovation policies for the benefit of Indonesian
patients and the economy.
IPMG member companies
Denmark: Novo Nordisk, France:Sanofi Group, Servier, Italy: Transfarma Medica Indah,
Japan: Astellas, Eisai, Meiji, Otsuka, Takeda, Mitsubishi-Tanabe, Switzerland: APL,
Mundipharma, Novartis, Roche, Germany: Boehringer-Ingelheim, Merck, Bayer, B-Braun,
Singapore: Wellesta, United Kingdom: Astra Zeneca, GlaxoSmithKline Pharma, USA: Abbott,
Johnson & Johnson, Merck Sharp and Dohme, Pfizer, Organon, Actavis.
Connect with IPMG
For further information on IPMG, please contact:
Office: Wisma Pondok Indah, 3rd Floor, Room 308, Jakarta Selatan - Indonesia
Mobile: +62 8161393433